Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.
Quoc-Dien Trinh, Daniel J George, Neal Shore, Egils Vjaters, David Olmos, Andrea Juliana P de Santana Gomes, Augusto Cesar de Andrade Mota, Natasha Littleton, Shankar Srinivasan, Frank Verholen, Kunhi Parambath Haresh, Fred Saad
Prostate Cancer Prostatic Dis 10.1038/s41391-026-01131-6
摘要
摘要
BACKGROUND: This analysis reports efficacy and safety data in the subgroup of Black patients from the ARANOTE phase 3 trial. METHODS: Patients starting on androgen-deprivation therapy (ADT) were randomised 2:1 to receive darolutamide 600 mg twice daily or placebo. Of the total ARANOTE population (N = 669), 65 patients (10%; darolutamide, n = 41; placebo, n = 24) were Black. RESULTS: In Black patients, darolutamide + ADT improved radiological progression-free survival (rPFS), reducing the risk of radiological progression or death by 49% vs ADT alone, consistent with the overall population. CONCLUSIONS: In Black patients from ARANOTE, darolutamide was associated with improvement in rPFS.
KM 提取结果
0 个 Figure · 0 个 KM 面板